The development of this technology is a key strategic area for Novo Nordisk in its effort to develop this next generation of insulin, which would lead to a safer and more effective insulin therapy. A GRI would help eliminate the risk of hypoglycaemia, the main risk associated with insulin therapy and one of the main barriers to achieving optimal glucose control.
Since the company was founded in Denmark more than 90 years ago, we have been changing diabetes.
Our key contribution is to discover, develop and manufacture better biological medicines and make them accessible to people with diabetes throughout the world. However, it takes more than medicine to defeat diabetes.
By partnering with patients, policymakers, healthcare professionals and non-governmental organizations we are addressing diabetes risk factors in urban areas, ensuring that people with diabetes are diagnosed earlier and that they have access to adequate care to be able to live their lives with as few limitations as possible.
Addressing the risk factors in cities With two-thirds of all people with diabetes living in urban areas1, cities are the frontline in the fight against diabetes. Cities influence how people live, travel and eat; factors which all have an impact on health.
To understand the root causes of type 2 diabetes and the social and cultural risk factors, Novo Nordisk has initiated the Cities Changing Diabetes programme in collaboration with a range of partners.
Ensuring earlier diagnosis Around million people have undiagnosed type 2 diabetes worldwide. On World Diabetes Daymore thanpeople were engaged in Novo Nordisk driven awareness and screening activities.
Novo Nordisk is working with partners to improve the availability, accessibility, affordability and quality of healthcare. Our largest investment in improving access to care is through our funding of the World Diabetes Foundationbut we also run specific corporate access to care programmes. Ensuring better outcomes Many people with diabetes do not achieve desired health outcomes4, which puts them at risk of developing diabetes-related complications.
While Novo Nordisk provides a broad portfolio of treatment options and delivery devices, we know that it takes more than medicine for people to live a full and healthy life with diabetes.
We address this by providing training of healthcare providers, education of people with diabetes and engaging in advocacy for patient-centred care.
Global report on diabetes. Br J Gen Pract. Actual rates of diagnosis, treatment, targets and outcomes vary in different countries.At Novo Nordisk, you will help patients around the vetconnexx.com you are interested in applying to Novo Nordisk and need special assistance or an accommodation to.
The Team Novo Nordisk mission is to inspire, educate and empower people affected by diabetes. We ride. We run. We swim. We race to change diabetes.
Dear Novo Nordisk Grant System User, The Grant Management System is unavailable until 10am EST on July 31st due to system maintenance and upgrades.
Novo Nordisk is an affiliate of Novo Nordisk A/S, one of the world s leading pharmaceutical companies. Novo Nordisk specializes in the development and production . "The OZEMPIC ® approval builds on Novo Nordisk's commitment to offering healthcare professionals a range of treatments that effectively addresses the complex needs of diabetes management and fits their patients' lifestyles," said Todd Hobbs, vice president and U.S. chief medical officer of Novo. Who we are. Novo Nordisk is a global healthcare company with 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases.
We are the holding company of the Novo Group and manage the investment assets of the Novo Nordisk Foundation. We invest in life science companies at all stages of development and in a broad portfolio of equity and fixed income securities.
Novo Nordisk manufactures, markets and/or distributes more than 21 drugs in the United States. Medications listed here may also be marketed under different names in different countries. Non-US country and region specific information is not available on this page.
Welcome to Novo Nordisk Resource Center. This web site will allow you to complete the required contracting process electronically, ensuring your contracted status as a Novo Nordisk speaker/Consultant.